<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:x="urn:schemas-microsoft-com:office:excel" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns:mv="http://macVmlSchemaUri" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Title" content="">
<meta name="Keywords" content="">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Courier New";
panose-1:2 7 3 9 2 2 5 2 4 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:Calibri;
color:windowtext;}
span.msoIns
{mso-style-type:export-only;
mso-style-name:"";
text-decoration:underline;
color:teal;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:346566715;
mso-list-template-ids:757732978;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style>
</head>
<body bgcolor="white" lang="EN-US" link="blue" vlink="purple">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri">Please feel free to distribute to interested colleagues.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:11.0pt;font-family:Calibri">Michael Twa, OD PhD </span></b><span style="font-size:11.0pt;font-family:Calibri"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri">Professor, Associate Dean for Research & Graduate Studies (<a href="http://www.uab.edu/optometry/home/vsgp">www.uab.edu/optometry/home/vsgp</a>)<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri">University of Alabama at Birmingham, School of Optometry (<a href="http://www.uab.edu/optometry/home/">www.uab.edu/optometry/home/</a>)<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri">Editor-in-Chief, Optometry and Vision Science (<a href="http://journals.lww.com/optvissci/pages/advancedsearch.aspx">www.optvissci.com/</a>)<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri">HPB 515 | 1716 University Boulevard | Birmingham, AL 35294-0010<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri">P: 205.934.6724 | mtwa@uab.edu <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:Calibri"><o:p> </o:p></span></p>
<div>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
<div>
<p class="MsoNormal"><span style="font-family:Arial"><img border="0" width="598" height="70" id="_x0000_i1025" src="http://ovs.edmgr.com/download.aspx?scheme=4&id=3"><br>
<br>
</span><strong><span style="font-size:13.5pt;font-family:Arial;color:white;background:teal">CALL FOR PAPERS </span></strong><strong><span style="font-size:13.5pt;font-family:Arial;background:teal">
</span></strong><span style="font-family:Arial"><br>
<br>
</span><strong><span style="font-size:13.5pt;font-family:Arial">Intraocular Pressure in Glaucoma
</span></strong><span style="font-family:Arial"><br>
<br>
<strong><span style="font-family:Arial">Submission window: May 1, 2017 to July 31, 2017</span></strong><br>
<strong><span style="font-family:Arial">Publication date: January 2018</span></strong><br>
</span><span style="font-size:9.0pt;font-family:Arial"> </span> <o:p></o:p></p>
<div>
<p class="MsoNormal"><span style="font-size:9.0pt;font-family:Arial">Glaucoma is a leading cause of irreversible blindness worldwide with an estimated prevalence of 3 million in the United States and more than 120,000 who are blind from this disease. The burden
of care associated with glaucoma—to patients and to our health care system—is enormous and growing. In 2010, the Centers for Disease Control estimated that there were more than 10 million visits per year to health care providers attributable to glaucoma. In
1998, the National Eye Institute Glaucoma Panel Report estimated that annual expenditures related to this disease were more than $1.5 billion and surely this has grown since then.<br>
<br>
Because glaucoma is such an important public health issue and because January has been designated as Glaucoma Awareness Month,
<em><span style="font-family:Arial">Optometry and Vision Science (OVS)</span></em> will devote our January issue to this topic over the next several years.<br>
<br>
This coming feature issue will focus on research related to intraocular pressure in glaucoma, a very broad and active field of investigation. The link between elevated intraocular pressure and glaucoma is so well-established that it has been characterized as
a causative disease factor. Moreover, lowering intraocular pressure remains the primary target for glaucoma therapy.<br>
<br>
<em><span style="font-family:Arial">Optometry and Vision Science</span></em> believes that it is timely to bring ongoing research efforts to publication in a feature theme issue that informs and advances thinking on this topic for researchers and clinicians
alike.<br>
<br>
<em><span style="font-family:Arial">Optometry and Vision Science </span></em>will publish study results from original research and clinical perspectives together in a single publication in January 2018. Submissions for this feature issue will be coordinated
by the Editor-in-Chief and a distinguished <strong><span style="font-family:Arial">Guest Editorial Team:
</span></strong><br>
<br>
<strong><span style="font-family:Arial">Andrew Mick, OD, FAAO</span></strong> (Associate Editor, and Feature Issue Lead Editor) – San Francisco Veterans Administration Hospital.<br>
<strong><span style="font-family:Arial">Douglas Anderson, MD </span></strong>(Guest Editor) – Professor Emeritus, Bascom Palmer Eye Institute<br>
<strong><span style="font-family:Arial">J. Crawford Downs, PhD </span></strong>(Guest Editor) – Professor, Vice-chair of Research; Director, Ocular Biomechanics and Biotransport Program, University of Alabama at Birmingham.<br>
<strong><span style="font-family:Arial">Laura Dreer, PhD</span></strong> (Guest Editor) – Associate Professor, Director, Psychological & Neuropsychology Clinical Research Services, University of Alabama at Birmingham.<br>
<strong><span style="font-family:Arial">Murray Fingeret, OD, FAAO</span></strong> (Guest Editor) – Chief of Optometry Section, Brooklyn/St. Albans Campus, Department of Veterans Administration New York Harbor Health Care System.<br>
<strong><span style="font-family:Arial">Thomas Freddo, OD, PhD, FAAO</span></strong> (Editorial Board Member) – Adjunct Professor at MCP Health Sciences University, Worcester, MA.<br>
<strong><span style="font-family:Arial">Chris Johnson, PhD, FAAO</span></strong> (Guest Editor) – Professor, University of Iowa. <br>
<strong><span style="font-family:Arial">John H.K. Liu, Ph.D. </span></strong>(Guest Editor) – Adjunct Professor of Ophthalmology, Director, Glaucoma Molecular Pharmacology Laboratory, University of California, San Diego.<br>
<br>
We anticipate that there will be great interest in this publication from clinicians as well as basic and clinical scientists.<br>
<br>
<strong><span style="font-family:Arial">Topics targeted for this issue include:</span></strong></span><o:p></o:p></p>
</div>
<ul type="disc">
<li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">Advances in anterior segment imaging emphasizing the anatomy, physiology, and pathology of glaucoma</span><o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">Novel drug mechanisms and advances in sustained-release medications for IOP control</span><o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">Advances in IOP measurement, including continuous monitoring, diurnal rhythms, etc.</span><o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">The influence of intracranial pressure, ocular perfusion pressure and IOP on glaucoma</span><o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">Ocular tissue biomechanics and IOP</span><o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">Care delivery models and the use of technology in screening/telemedicine</span><o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
<span style="font-size:9.0pt;font-family:Arial">The role of patient adherence and health behaviors in glaucoma therapy</span><o:p></o:p></li></ul>
<div>
<p class="MsoNormal"><span style="font-size:9.0pt;font-family:Arial">Articles will be selected for the Feature Issue by the Guest Editorial team and the Editor-in-Chief based on quality and topical relevance. All papers accepted in the peer review process will
be published in <em><span style="font-family:Arial">OVS </span></em>in a timely fashion. The window of opportunity for
<strong><span style="font-family:Arial">manuscript submission is May 1, 2017, to July 31, 2017</span></strong>. Early submissions are encouraged; and will receive priority for E-publication on the journal website (<u><a href="http://www.optvissci.com">www.optvissci.com</a></u>).
<strong><span style="font-family:Arial">Publication date: January 2018.</span></strong><br>
<br>
All manuscripts will be peer reviewed and must be submitted online at <a href="http://ovs.edmgr.com/">
http://ovs.edmgr.com.</a></span><o:p></o:p></p>
</div>
</div>
<p class="MsoNormal"><span style="font-size:9.0pt;font-family:Arial"> <br>
Submissions must be prepared according to the Instructions for Authors available at
<a href="http://edmgr.ovid.com/ovs/accounts/ifauth.htm">http://edmgr.ovid.com/ovs/accounts/ifauth.htm</a>. During submission, in the “Author’s Comments” box, note that your paper is being submitted for consideration of this Feature Issue.<br>
<br>
Contact the Editorial Office (<u><a href="mailto:ovs@osu.edu">ovs@osu.edu</a></u>) for any questions.<br>
<br>
Michael D. Twa<br>
Editor-in-Chief<br>
<em><span style="font-family:Arial">Optometry and Vision Science</span></em></span>
<o:p></o:p></p>
</div>
</body>
</html>